Abstract: In Symptom-free patients with allergies, a subclinical inflammatory state has been described, in which subthreshold doses of an allergen have been found to cause inflammatory cell infiltration into the nasal mucosa. This includes increases in the levels of cellular adhesion molecules, nasal and conjunctival eosinophilia, and other markers of inflammation, which do not result in overt allergic symptoms. While allergic rhinitis(AR)treatment is typically guided by the need to reduce symptoms, the treatment strategies that reduce inflammation during asymptomatic periods may have positive effects on the onset, progression, and severity of AR. Therefore, treatment options that target underlying inflammation along with symptom relief should be considered. There are three major classes of commonly used AR medications, namely, intranasal corticosteroids, antihistamines, and antileukotrienes. Among these, intranasal corticosteroids appear to be the most reasonable therapeutic option in patients who would benefit from continuous inhibition of persistent inflammation.

Key words: Allergic rhinitis, Glucocorticoids, Inflammation, Anti-allergic agents, Drug therapy